Curis Inc. (CRIS)

1.45 +0.02 (+1.399%)

IEX Real-Time Price

August 17, 2018 EST.

NASDAQ Global Market : Healthcare

Prev Close 1.43

Price Open 1.44

Volume: 71,055

Avg Volume: 247,346

Market Cap: 48.11M

P/E Ratio -1.03

52 Wk Range 1.4-11.35



CRIS Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-07-31
29.81M
1.06M
5.12
3.54%

2018-07-13
29.75M
931,138
2.05
3.13%

2018-06-29
29.75M
1.09M
1.56
3.65%

2018-06-15
29.75M
1.33M
2.24
4.47%




CRIS Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-05-03
Q1 2018
N/A
-0.08 (2)
-0.07
0.01

2018-03-08
Q4 2017
N/A
-0.09 (3)
-0.07
0.01

2017-11-07
Q3 2017
BTO
-0.09 (3)
-0.07
0.01

2017-08-03
Q2 2017
BTO
-0.09 (3)
-0.07
0.01

News

Curis, Inc. (CRIS) CEO Ali Fattaey on Q2 2018 Results - Earnings Call Transcript (2018-08-02 11:49 SeekingAlpha)

Curis, Inc. (CRIS) Q2 2018 Earnings Conference Call August 2, 2018 08:30 AM ET Executives Ali Fattaey - President and CEO James Dentzer - CFO and CAO Analysts Adnan Butt - Guggenheim Securities Peter Lawson - SunTrust Robinson Humphrey Presentation Operator Good m…

 

Curis Q2 revenues up 14%; shares up 8% premarket (2018-08-02 08:52 SeekingAlpha)

Curis ( CRIS ) Q2 results : Revenues: $2.4M (+14.3%). More news on: Curis, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more …

 

Curis beats by $0.13, beats on revenue (2018-08-02 07:03 SeekingAlpha)

Curis (NASDAQ: CRIS ): Q2 EPS of -$0.26 beats by $0.13 . More news on: Curis, Inc., Earnings news and commentary, Healthcare stocks news, , Read more …

 

Curis Reports Second Quarter 2018 Financial Results (2018-08-02 07:00 PR Newswire)

LEXINGTON, Mass. , Aug. 2, 2018 /PRNewswire/ --Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today reported its financial results for the second quarter ended June30,…

 


Statistics

Shares Outstanding: 33.18M

Top 15 Institution Percent: 5.70

Price To Sales: 4.49

Price To Book: 6.77

Revenue: 2.44M

Gross Profit: 2.32M

Cash: 69.38M

Debt: 42.87M

Return On Assets: -73.34

Return On Equity: -525.11

Profit Margin: N/A

Price History

Beta: 1.08

50-day Moving Avg: 1.86

200-day Moving Avg: 3.12

YTD Change: -60.92

5-day Change: -8.23

1-month Change: -17.14

3-month Change: -47.26

6-month Change: -46.56

1-year Change: -83.33

Revenue Per Share: 0.00

Revenue Per Employee: 44436.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Curis Inc.

Exchange: NASDAQ Global Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.curis.com

Curis Inc is a biotechnology company engaged in developing and commercializing drug candidates for the treatment of human cancers. Its pipeline products include CUDC-907, CA-170, CA-4948, CA-327, and Erivedge.